GlassScriptPhysician profile
Devendra M Sharma
NPI 1811061211
$3,074.87
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $203 · 2021: $733 · 2022: $250 · 2023: $461 · 2024: $178 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $846.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $450.34 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $408.61 | 2019-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $362.16 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $167.13 | 2023 | Purified Cortrophin Gel |
| Stryker Corporation | $136.53 | 2024 | Mako |
| Nevro Corp. | $126.64 | 2023 | Senza |
| Glaxosmithkline, LLC. | $125.01 | 2022 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $124.97 | 2019 | |
| Sunovion Pharmaceuticals INC. | $55.64 | 2020 | |
| Astellas Pharma US INC | $20.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.